Outcomes of oesophageal cancer treated with neoadjuvant compared with definitive chemoradiotherapy.
10.47102/annals-acadmedsg.2020633
- Author:
Caryn WUJANTO
1
;
Jeremy TEY
;
Balamurugan VELLAYAPPAN
;
Jimmy SO
;
Wei Peng YONG
;
Asim SHABBIR
;
Michelle TSENG
;
Yu Yang SOON
;
Francis HO
Author Information
1. Department of Radiation Oncology, National University Cancer Institute, Singapore.
- Publication Type:Journal Article
- MeSH:
Chemoradiotherapy;
Esophageal Neoplasms/pathology*;
Humans;
Middle Aged;
Neoadjuvant Therapy;
Neoplasm Recurrence, Local;
Neoplasm Staging;
Retrospective Studies
- From:Annals of the Academy of Medicine, Singapore
2021;50(7):536-547
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTION:We report outcomes of patients with oesophageal cancer treated with neoadjuvant chemoradiotherapy (NACRT) plus surgery or definitive chemoradiotherapy (chemoRT) at our institution.
METHODS:We retrospectively reviewed patients who underwent chemoRT from 2005 to 2017. The primary outcome was overall survival (OS). Secondary outcomes were disease-free survival (DFS) and toxicities.
RESULTS:We identified 96 patients with median age of 64 years and squamous cell carcinoma in 82.3%. Twenty-nine patients (30.2%) received NACRT plus surgery, 67 patients (69.8%) received definitive chemoRT. Median follow-up was 13.5 months. The 3/5-year OS were 26.4%/13.4%, and 59.6%/51.6% in the definitive chemoRT and NACRT plus surgery groups, respectively. The 3/5-year DFS were 19.3%/12.3%, and 55.7%/37.2% in the definitive chemoRT and NACRT plus surgery groups, respectively. NACRT plus surgery significantly improved OS (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.22-0.72,
CONCLUSION:NACRT plus surgery improved OS and DFS. However, in view of treatment-related complications, careful selection of patients is warranted. With the predominant histology of our cohort being squamous cell carcinoma (SCC), our results may be more relevant for those with SCC.
